Drugs / Tetanus Diptheria Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05077137 | Sep 2021 → Jul 2027 expected | melanoma | Duke University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05294588 | Apr 2022 → Feb 2026 | gonorrhea | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus Diptheria Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077137 ↗ |
| Modality | Vaccine | “The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.” NCT05077137 ↗ |
| Route | Intramuscular | “administered as 0.5 mL intramuscular injection” NCT05077137 ↗ |